Rize Oncology Inc.
CNSX
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 1.18% | 26.45% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 50.06% | 31.95% | |||
| Operating Income | -50.06% | -31.95% | |||
| Income Before Tax | -56.05% | -32.25% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -56.05% | -32.25% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -56.05% | -32.25% | |||
| EBIT | -50.06% | -31.95% | |||
| EBITDA | -- | -- | |||
| EPS Basic | 18.18% | -33.33% | |||
| Normalized Basic EPS | 14.81% | -28.57% | |||
| EPS Diluted | 18.18% | -33.33% | |||
| Normalized Diluted EPS | 14.81% | -28.57% | |||
| Average Basic Shares Outstanding | 88.23% | 0.00% | |||
| Average Diluted Shares Outstanding | 88.23% | 0.00% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||